OriginBio Health is a distinctive local health management enterprise, leveraging the dual advantages of genetic testing and cell technology. With a core model of “pre-examination and post-management + full-process service,” it has built a comprehensive “prevention-diagnosis-intervention-rehabilitation” closed-loop system. The company not only provides personalized health solutions for clients but also strives to create a complete cell industry ecosystem, aiding in high-quality economic transformation. Due to its profound capabilities, it was elected as a council member of the National Cell Therapy Industry and Clinical Research, firmly establishing its position as an industry benchmark.

On the service side, the company integrates precision throughout the entire process. Before testing, it innovatively adopts a “1+X” examination model where “1” represents basic health coverage with routine items, while “X” involves specialized tests customized by professional doctors based on individual conditions to ensure specificity. Post-testing, for significant positive results, it initiates a closed-loop management of “screening-assessment-follow-up-consultation-post-treatment follow-up,” achieving goals of preventing major diseases and managing chronic conditions. Based on genetic data and health status, it customizes intervention plans using biological cell therapy to precisely repair cells and boost immunity. Services cover areas such as premature ovarian failure and diabetes, and stem cell technology is used to achieve multi-organ damage reversal, meeting anti-aging and chronic disease management needs.

Technological innovation is at the heart of its competitiveness. The company’s independently developed fully automatic cell preparation instrument and fourth-generation nano sequencer are exclusive to Henan, significantly enhancing detection accuracy and efficiency. In June 2025, the “Concentrated Bone Marrow Cell Preparation and Application Guidelines” group standard, which the company led in drafting, was published on the International Standards Network. This standard is 100% original and fills a domestic gap.

In terms of industrial layout, the company has established two main bases in Zhengzhou and Shenzhen, focusing on the R&D of fully automated cell preparation equipment and breaking through bottlenecks in upstream core technologies. Compared to peers, it has taken the lead in laying out the upstream supply chain, forming a complete industrial chain from “upstream intelligent equipment - midstream cell preparation and storage - downstream clinical application.” Its cooperation network spans hospitals, universities, and other institutions, continuously leading high-quality industrial development.